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Background: Focal segmental glomerulosclerosis (FSGS) is a glomerular scarring disease diagnosed mostly by
kidney biopsy. Since there is currently no diagnostic test that can accurately predict steroid responsiveness in FSGS,
prediction of the responsiveness of patients to steroid therapy with noninvasive means has become a critical issue.
In the present study urinary proteomics was used as a noninvasive tool to discover potential predictive biomarkers.
Methods: Urinary proteome of 10 patients (n = 6 steroid-sensitive, n = 4 steroid-resistant) with biopsy proven FSGS
was analyzed using nano-LC-MS/MS and supervised multivariate statistical analysis was performed.
Results: Twenty one proteins were identified as discriminating species among which apolipoprotein A-1 and
Matrix-remodeling protein 8 had the most drastic fold changes being over- and underrepresented, respectively, in
steroid sensitive compared to steroid resistant urine samples. Gene ontology enrichment analysis revealed acute
inflammatory response as the dominant biological process.
Conclusion: The obtained results suggest a panel of predictive biomarkers for FSGS. Proteins involved in the
inflammatory response are shown to be implicated in the responsiveness. As a tool for biomarker discovery, urinary
proteomics is especially fruitful in the area of prediction of responsiveness to drugs. Further validation of these
biomarkers is however needed.
Keywords: Urine proteomics, Inflammatory response, ResponsivenessBackground
Focal segmental glomerulosclerosis (FSGS) is a glomeru-
lar scarring disease characterized by increased extracel-
lular matrix within the glomerular tuft [1,2]. The
sclerotic lesions occur focally and in only some segments
of glomeruli, and are typically not associated with im-
mune complex deposition [1]. It is believed that the loss
of foot process of podocytes is also one of the most im-
portant characteristics of FSGS [3]. FSGS is a major
cause of steroid resistant nephrotic syndrome, which* Correspondence: Roman.Zubarev@ki.se
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unless otherwise stated.could lead to end-stage renal failure [4,5]. FSGS is cur-
rently diagnosed mostly by kidney biopsy [1,2]. Patho-
logical evaluation of renal cortical tissue using renal
biopsy has become a traditional way to distinguish be-
tween steroid sensitive and steroid resistant patients,
since there are no clinical or biochemical parameters for
distinguishing between them [6,7]. Owing to the invasive
nature and potential complications of biopsy and also
lack of absolute correlation between histological findings
and patients’ clinical response to treatment [8], identifi-
cation of noninvasive biomarkers would be most benefi-
cial for steroid-resistant patients, who would avoid
exposure to high-dose, yet ineffective steroid courses.
It is therefore essential to search for noninvasive bio-
markers for the prediction of steroid responsiveness ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cause of steroid-resistant nephrotic syndrome. Urine is
the most appropriate fluid sample for biomarker dis-
covery in glomerular diseases [9]. Proteomics, with its
high-throughput capabilities, is the optimal technique
for searching predictive biomarkers in urine. Although
large efforts have been made in this field in recent years
[10,11], the emergence of the latest high-resolution
mass spectrometry tools promises deeper and more
accurate analysis that should provide more reliable bio-
markers and possibly even shed some light on the dis-
ease mechanism.
In this study, we applied urine proteomics using a com-
bination of nanoflow liquid chromatography and a high
resolution mass spectrometer to identify biomarkers pre-
dictive of FSGS patient responsiveness to steroid therapy.
Multivariate statistical analysis was employed to identify
the relevant proteins and build a predictive model, and
gene ontology enrichment and upstream regulator analysis
provided insight into FSGS-related biological processes.
However, since a relatively small cohort was used in this
pilot study, further analysis of a larger cohort is required
to validate these findings.
Methods
Patients
At Labbafinejad Hospital, 10 patients (six steroid sensi-
tive and four steroid resistance) with biopsy proven
FSGS were consecutively enrolled in this study during
2011. The samples were coded to protect confidentiality.
Age, sex, smoking habits and also diet (a day before
sampling) of the patients were noted and patients with
other implications like diabetes were excluded. All pa-
tients agreed to the use of their urine samples for this
study. Written consents were given by the participants
according to the recommended procedure and consent
form provided by the medical ethics committee of the
Shahid Beheshti university of medical sciences. The con-
sent forms signed by each participant signed included
the following issues: brief introduction of the study, its
benefit to research, potential dangers, confidentiality
of the identity of participants, contact information for
answering eventual questions, and the right to resign
from the study. The Medical ethics committee of Shahid
Beheshti university of Medical sciences approved this
consent forms as well as this study (date of approval: 12/
17/2010). For each patient, data were collected concern-
ing serum creatinine, eGFR (by CKD-EPI equation),
presence of hypertension and proteinuria at presenta-
tion. All the patients had same the race/ethnicity.
The patients were treated with prednisolone 1 mg/kg for
6 to 8 weeks and 24 hours urine samples were collected
for evaluation of the response to treatment. Complete re-
mission was defined as urine protein excretion less than200 mg per day and partial response is referred to a 50%
reduction in proteinuria. While KDIGO guidelines define
steroid-resistance in adults as presence of proteinuria des-
pite high-dose prednisolone for >4 months, we consider
16 weeks of high-dose therapy too long a period that may
negatively affect nonresponding patients. According to the
policy of our Center, if a patient shows no response to high
prednisolone in 8 weeks, the immunosuppressive therapy
protocol must be changed to avoid the side effects of high
dose steroids.
Sample preparation and protein extraction
All the urine samples were taken at the time of diagnosis
and before the initiation of treatment. Approximately
20–40 mL of second morning midstream urine from pa-
tients were collected from the subjects. Urine samples
were immediately put on ice and 1 mL of dissolved pro-
tease inhibitor (one tablet, Cocktail protease inhibitor,
Sigma, dissolved in distilled water) was added to each
10 mL of urine. The samples were centrifuged at 3000
rcf for 20 minutes at 4°C to pellet the cell debris. The
supernatant was divided and transferred into 15 mL
tubes and stored at −80°C until the samples were proc-
essed further. The supernatant was concentrated and
desalted by ultrafilteration as follow: urine samples were
transferred to individual Amicon Ultra-15 Centrifugal
Filter Units with a 3 kDa cutoff (Millipore, Billerica,
MA, USA) and spun at 3220 rcf at 4°C for 1 h. The ini-
tial concentration was followed by two wash steps by
adding 14 mL of PBS and spinning each tube at 3220 rcf
at 4°C for 1 h. By filtering, the sample volume was re-
duced from 15 mL to a final volume of approximately
800–1000 μL. In order to inactivate potential bacterial
activity, 1200 μL of cold acetone was added to 300 μL of
concentrated urine and incubated at −20°C overnight.
The samples were dried in a vacuum concentrator and
stored at −20°C.
Dried samples were re-suspended in 0.1 M ammonium
acetate (pH 5) and the protein concentrations of the
samples were determined using the BCA (Bicinchoninic
Acid) Protein Assay (Pierce, Thermo Scientific, USA).
10 μg urinary proteins from the individual samples were
resolved in a buffer containing 0.1% ProteaseMax, 10%
acetonitrile, 1 M urea and 50 mM ammonium bicarbon-
ate and digested in duplicates using sequencing-grade
trypsin (Promega, USA). Samples were then reduced
with 20 mM DTT (dithiothreitol) for 30 min at 56°C
and alkylated with 66 mM IAA (Iodoacetamide) for
30 min at room temperature in the dark. The samples
were digested by trypsin in a ratio of 1:50 (enzyme: pro-
tein) at 37°C overnight. The resulting peptides were
desalted using C18 StageTip (Thermo Scientific, USA).
The eluted peptides were evaporated in a SpeedVac and
re-suspended in a buffer containing 0.1% formic acid
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LC-MS/MS system.
Liquid chromatography tandem mass spectrometry
Liquid chromatography tandem mass spectrometry
(nLC-MS/MS) analyses were performed on an Easy-nLC
system coupled online to a Q Exactive mass spectrom-
eter (both - Thermo Scientific, Bremen, Germany).
Separation of peptides was performed using a 10 cm
fused silica tip column (SilicaTips™ New Objective Inc.,
Woburn MA, USA) in-house packed with Reprosil-Pur
C18-AQ 3 μm resin (Dr. Maisch GmbH, Ammerbuch-
Entringen, Germany) using a methanol slurry and a
pressurized “packing bomb” operated at 40 bar (Proxeon
Biosystems). Mobile phases consisted of 0.1% formic
acid in water v/v (buffer A) and 0.1% formic acid in
acetonitrile v/v (buffer B). The LC gradient was set up
as following: 5 − 35% buffer B in 89 min, 48 − 80% buffer
B in 5 min, and 80% buffer B for 8 min, all at a flow
rate of 300 nL/min. Samples (10 μL corresponding to
approximately 2.3 μg of total protein) were injected via
a temperature-controlled autosampler.
The MS acquisition method was comprised of one sur-
vey full scan ranging from m/z 300 to m/z 1650 acquired
with a resolution of R = 70,000 at m/z 400, followed by
data-dependent HCD (higher energy collision dissoci-
ation) MS/MS of maximum ten most abundant precur-
sor ions with a charge state ≥ 2. MS/MS spectra were
acquired with a resolution of R = 17,500, with a target
value of 2e5 ions, isolation m/z width was set to 4 and
normalized collision energy to 26 eV. For all sequencing
events, dynamic exclusion was enabled and unassigned
charge states were rejected. The instrument was cali-
brated externally according to the manufacturer’s in-
structions and all data were acquired using internal lock
mass calibration on m/z 429.088735 and 445.120025
(background ions). All the experiments were done in du-
plicate (20 runs in total).
Protein identification and quantification
Tandem mass spectra were extracted using Raw2MGF
(in-house-written program) and the resulting Mascot
generic files (.mgf) were searched against a concatenated
SwissProt protein database (Human taxonomy) using
Mascot 2.3.0 search engine (Matrix Science Ltd., London,
UK). Carbamidomethylation of cysteine was set as a fixed
modification and deamidation of asparagine and glutam-
ine as well as oxidation of methionine were set as variable
modifications. Up to two missed tryptic cleavages were
allowed and the mass tolerance was set to 10 ppm and to
0.05 Da for the precursor and fragment ions, respectively.
Only peptides having individual MS/MS Mascot score
above significant threshold corresponding to E < 0.05 were
accepted. Only proteins identified with at least two uniquepeptides with a significant score and at 0.25% false discov-
ery rate (FDR) were considered for further quantification.
Relative abundance of these proteins was determined
using Quanti software (an in-house developed software
package [12]), which performs accurate label-free pep-
tide and protein quantification with correction for
instrumental response fluctuations. The areas of the
chromatographic peaks were taken as the peptide abun-
dances and the same peptides were quantified in each
nLC-MS/MS data file using accurate mass and the order
of elution as identifiers. The sum of the abundances of
all unique peptides of a protein was used as the protein
abundance value. The list of quantified proteins was
further filtered to 1% FDR, which corresponded to the
protein Mascot score of 23.73.
Statistical analysis
Prior to statistical analysis, the data were transformed
(log2) in order to make normal distribution of data which
is a prerequisite for parametric statistical tests and deleted
all the proteins with at least one missing value. The quanti-
tative proteome data was subjected to multivariate statis-
tical analysis using SIMCA (SIMCA-p 13.0, Umetrics,
Umeå, Sweden). The protein abundances from each repli-
cate analysis were used as the primary variables and 10 pa-
tient samples were considered as primary observations.
The analysis was performed on unit variance scaled data,
assuming equal importance of each protein regardless of
their relative abundance and magnitude of variance be-
tween the samples. Unsupervised principal component
analysis (PCA [13,14])) was performed for detecting the
clusters of the data if any and identifying statistical outliers.
PCA explains the variance-covariance structure of a
set of variables by using linear combinations of those
[15]. The linear combination represents a new coordin-
ate system that is obtained by rotating the original vari-
able space. The new axes acquired will represent the
directions with maximum variability where PC1 indi-
cates the direction of the highest variability followed by
consecutive PCs with diminishing variability orthogonal
to the previous PC or PC plane [16]. For classification
and identification of proteins separating steroid resistant
from steroid sensitive patients, we used orthogonal pro-
jection to latent structures discriminant analysis (OPLS-
DA) [17]. The OPLS analysis detects the proteins whose
abundances covary with the defined clinical group.
OPLS-DA model was built for discrimination of re-
sponder and non-responder groups. To avoid overesti-
mation, sevenfold cross-validated scores were calculated
[18]. These scores were used for receiver operating char-
acteristic (ROC) analysis to estimate the predictive ac-
curacy of the model [19]. As a negative control,
responder/non-responder identifier was randomized for
all samples, and the above procedure was repeated.
Kalantari et al. BMC Nephrology 2014, 15:141 Page 4 of 10
http://www.biomedcentral.com/1471-2369/15/141Protein GO-term enrichment and regulator analysis
For general characterization of properties of the proteins
in the data set and also detection of the enriched cellular
component, molecular function and biological process,
gene ontology enrichment was performed using DAVID
open-source software tool [20]. DAVID uses the EASE
score [21], a modified Fisher Exact p-value, to determine
whether a GO-term is over- or under-represented in a
given proteomic data set with reference to a background
data set (e.g. the human proteome). A cut off for enrich-
ment score for DAVID software result was set at 1.3 and
the redundant hits were excluded.
Results
Clinical and pathological characteristics of patients
Clinical and laboratory information on patients is pro-
vided in Table 1. Ten patients (six males and four fe-
males, aged between 18–61 years, mean age 37.1 years)
with biopsy-proven FSGS were enrolled. A single path-
ologist reviewed the biopsy samples. In order to estimate
the amount of protein excretion, 24-hour urine collec-
tion was used. The mean 24-hour protein concentration
was 3720 mg/day. Renal function was evaluated by eGFR
using CKD-EPI equation. The mean eGFR level was
63.6 cc/min/1.73 m2 and five patients had eGFR less
than 60 cc/min/1.73 m2 at presentation. All the patients
were HIV negative. No morbidly obese patients were in-
cluded. There was no evidence of secondary FSGS on
pathology samples. The p-values for the relationship be-
tween clinical features and responsiveness were not sig-
nificant: for age (p-value = 0.34); eGFR (p-value =0.21);
proteinuria (p-value =0.7); TA/IF (p-value =0.09); global
glomerulosclerosis (p-value =0.9).
Proteomics analysis
After false discovery rate (FDR) assessment (≤1%) using
in house-written software which was also used forTable 1 Demographic and laboratory characteristics of patien
Patient’s code Age (yr) Sex eGFR (cc/min/1.73 m2) Proteinuria
1 29 M 34.61 2031
2 46 M 34.64 5000
3 19 M 145.76 4500
4 61 M 46.52 2590
5 37 F 78.51 1400
6 36 F 60.52 2710
7 37 F 42.01 710
8 30 M 38.76 2925
9 58 F 70.48 4373
10 18 M 85.17 1100
(eGFR: Estimated Glomerular Filtration Rate by CKD-EPI equation, TA: tubular atroph
responder group.quantification [12], 368 protein entries, each with ≥2
unique peptides, were quantified (Additional file 1). The
data set after preprocessing procedure reduced to 110
protein entries (Additional file 2).
Unsupervised statistical analysis by PCA
The dataset produced a single cluster in two-dimensional
PCA, without any outlier (Figure 1). The PCA coordinates
did not correlate with patients’ sensitivity to treatment,
sex or any other known to us baseline parameter or clin-
ical characteristics. The lack of clustering in PCA score
plot means that there was no confounding factor that af-
fected our study, and that the difference between re-
sponders’ and non-responders’ proteomes was relatively
small. Therefore, supervised orthogonal projection to la-
tent structures discriminant analysis (OPLS-DA) was used
to reveal these differences.
Supervised statistical analysis by OPLS-DA
110 proteins were normalized in both groups with
FDR ≤ 1% and the other requirements described above
(Additional file 2). OPLS-DA model gave R2 = 0.996 and
Q2 = 0.756 for the discrimination of responder and non-
responder groups, and showed the predictive accuracy of
100% (Figure 2). 21 proteins significantly contributing
to the responder/non-responder discrimination by the
OPLS-DA model. These proteins are listed in Additional
file 3 with their average responder/non-responder abun-
dance ratio for each protein. 13 proteins were underrepre-
sented and eight proteins overrepresented in responders
compared to non-responders.
In the negative control, where responder/non-re-
sponder identifiers were randomized for all samples, no
valid OPLS-DA model (R2 = 0.694, Q2 = −0.216) was ob-
tained, and cross-validation confirmed that the model is
statistically indistinguishable from random guessing with
the area under the curve (AUC) of only 0.59 (Figure 3).ts with focal segmental glomerulosclerosis
(mg/day) TA/IF Global glomerulosclerosis Responsiveness
<10% 0% Partial Responder
30% 30% Non-responder
30% 23% Partial Responder
<10% 16% Partial Responder
<10% 8% Partial Responder




0 <10% 0% Complete Responder
y, IF: interstitial fibrosis). All the partial responders were included in the
Figure 1 Score plot of PCA. Open circles represent steroid sensitive (responder) and black dots represent steroid resistant (non-responder)
patient samples. Each of the 10 samples was analyzed with two technical replicates.
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cross-validated predictive model on Figure 2.
GO-term enrichment analysis
Gene ontology enrichment analysis of the 21 most differ-
entiating proteins obtained from the predictive OPLS-DA
model, using DAVID software revealed “acute inflamma-
tory response” (p-value = 1. 9 × 10−4), “defense response”
(p-value = 5.5 × 10−4), “response to wounding” (p-value =
2.9 × 10−3) and “homeostatic process” (p-value =5.6 × 10−2)
as the most significant biological processes (Figure 4) (see
the details in Additional file 4). In pathway analysis, no
enriched signaling or metabolic pathway was found.
Discussion
A noninvasive biomarker from urine sample that pre-
dicts responsiveness to steroid therapy in focal segmen-
tal glomerulosclerosis would be valuable for choosing
the correct therapeutic strategy which should lead to re-
duced time of healing.
Urine proteomics can be utilized to identify a panel of
biomarkers associated with steroid resistance in FSGS.
We performed nLC-MS/MS using high resolution mass
spectrometer (Q-Exactive) and used supervised multivari-
ate statistical analysis to identify proteins differentiating
the two groups. In the list of the identified candidates,
some proteins have been reported before, but most mole-
cules are novel and thus need to be further validated on a
larger cohort. Relationship between some of these bio-
markers and responsiveness to steroid therapy as well as
glomerular sclerosis is discussed below.The most significantly overrepresented protein in the
steroid sensitive group (responders) was APOA1 (apoli-
poprotein A-1) (fold change = 3.15). Kunitake et al. have
found in 1992 that all transition metal ions binding to
lipoprotein (A-I) (which contains APOA1) are known li-
gands of transferrin or ceruloplasmin [22], with both lat-
ter proteins also included in the list of predictive
proteins. The complexes of lipoprotein (A-I) with these
ions appear to contain transferrin and ceruloplasmin
and to inhibit oxidation of LDL in vitro. Since it is
believed that LDL oxidation is a key element in the ath-
erosclerotic process, high excretion of APOA1 and
transferrin in urine of the steroid sensitive patients may
reflect higher content of these proteins in serum of these
patients, which suggests that steroid sensitive group
might have milder sclerosis potential. Comparison of
sclerosis status in Table 1 supports this hypothesis (with
100% sensitivity and 75% specificity), the only exception
being patient 9 whose biopsy might have been taken
from a non-sclerotic part.
MXRA8 (Matrix-remodeling protein 8) was the most
significantly underrepresented protein (fold change 1.5)
in steroid sensitive patients. Matrix-remodeling proteins
are believed to associate with the fibrosis process in
heart disease [23]. Significant underrepresentation of
MXRA8 may reflect the higher prevalence of interstitial
fibrosis (IF) in non-responders (Table 1). Indeed, three
out of four non-responders have IF >10%, while four out
of six responders have IF <10%.
Among the proteins in the predictive list (Additional
file 3) are CUBN, IGHG1, CERU, TFRE and A2GL,
Figure 2 Predictive model. A) Orthogonal projection to latent structures discriminant analysis (OPLS-DA) model for discrimination of steroid
sensitive (open circles) and steroid resistant (black dots) patient samples. B) Separation of the same samples by a seven-fold cross validated model
built based on OPLS-DA in A); C) ROC-curve based on model in B).
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Figure 3 Randomized model. A) OPLS-DA model for the decoy discrimination of steroid sensitive (open circles) and steroid resistant (black dots)
patient samples. B) Separation of the same samples by a seven-fold cross validated model built based on OPLS-DA in A); C) ROC-curve based on
model in B).
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Figure 4 Gene set enrichment analysis of biological process.
This analysis was done by DAVID based on the predictive proteins in
Additional file 3.
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kidney disease [24]. CUBN (Cubilin) is highly expressed
in the renal proximal tubule and the visceral yolk sac [25]
and other tissues. Cubilin was shown to be an endocytic
receptor for apolipoprotein A-I (apoA-I)/high density lipo-
protein (HDL), mediating uptake of HDL in the kidney
and visceral endothelium [26,27]. Other cubilin ligands in-
clude albumin, transferrin, immunoglobulin light chains,
vitamin D-binding protein, myoglobin, galectin-3 and
Clara cell secretory protein [28]. Underrepresentation of
CUBN in our data set which correlates with overrepresen-
tation of APOA1 and TRFE (as ligands for CUBN) leads
us to the hypothesis that the capacity of kidney and other
CUBN-expressing tissues for APOA-1 uptake and binding
to TRFE is decreased in the steroid sensitive compared to
steroid resistant group. Elevated excretion level of IGHG1
(a ligand for CUBN) also may be linked to underrepresen-
tation of CUBN.
Four of the predictive proteins (CLUS, A1AG2, AACT
and TRFE) were enriched in the GO process “acute in-
flammatory response” as the most significant biological
process according to DAVID. Implication of inflamma-
tion in pathogenesis of FSGS has been found in some
studies [29,30]. Scandrett et al. in 1995 reported the de-
pendence of glomerulosclerosis following antiglomerular
basement membrane nephritis to the degree of acute
inflammatory injury [31]. Tsai et al. have recently investi-
gated the anti-inflammatory effect of a traditional drug in
FSGS treatment [29].CLUS (Clusterin) is a ubiquitous protein and is a com-
ponent of the high-density lipoprotein (HDL) complex
with putative functions in the transport of lipids, apop-
tosis, protection of cells from stress and, most import-
antly, in the regulation of complement activity [32].
Previous studies indicate that clusterin also may have
some pathogenic role in FSGS [32]. In fact, clusterin has
been recognized as one of the most active physiological
inhibitors [33] of the hitherto uncharacterized circulat-
ing plasma factor that is the putative cause of the disease
[34,35]. Thus, its deficiency should negatively affect pro-
teinuria in this condition. Therefore, underrepresenta-
tion of urinary clusterin in steroid sensitive patients may
explain the higher level of proteinuria in these patients
(mean = 4038 mg/day) compared to the steroid resistant
group (mean = 3259 mg/day).
A1AG2 (Alpha-1-acid glycoprotein 2) is an acute-phase
protein; its blood concentration is therefore significantly
increased in inflammatory states [36]. This protein has
been reported as a urinary biomarker of glomerular dis-
ease [37]. In cancer studies, increased α1-acid glycoprotein
levels have been interpreted as the presence of inflamma-
tion that complicated the treatment regime [38,39]. Slight
overrepresentation of A1AG2 in the urine of steroid re-
sistant patients may reflect its higher concentration in
blood, which in turn may be due to a more severe inflam-
matory status of these patients. The latter suggestion is
supported by the enrichment of the “acute inflammatory
response” process in that patient group compared to ster-
oid sensitive patients.
AACT (alpha-1-antichymotrypsin) is a glycoprotein in
plasma which is primarily synthesized in hepatocytes
and acts as a protease inhibitor [40]. The expression of
α1-antichymotrypsin in hepatic cells is known to be en-
hanced by glucocorticoids (steroids) [40]. Overrepresen-
tation of this protein in the urine of steroid sensitive
patients is thus an expected result, reflecting correlation
between this protein and steroids.
Urine excreted AACT (α1-antichymotrypsin) has been
found before in kidney disease and suggested as a poten-
tial new urinary biomarker for diagnosing allograft rejec-
tion after renal transplantation [41].
PGBM, also known as perlecan or endorepellin, is one
of the components of basement membrane of various
tissues, especially glomeruli in kidney [42,43]. This is a
key molecule in the charge-selective moiety of glomeru-
lar filtration [44,45]. Rienstra et al. reported correlation
of perlecan expression with severity of interstitial fibrosis
and also sclerotic lesions of FGS [46]. Increased excre-
tion of this protein in responders may reflect different
status of glomerular filtration in this group in compari-
son with non-responders.
ACTG (gamma-actin) is the monomeric component of
the two-stranded helical structural filament, filamentous
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with numerous other costameric proteins, including
talin and vinculin [47]. Foot process effacement is re-
lated to derangements in podocyte actin cytoskeleton
and glucocorticoids (steroids) ameliorate proteinuria by
stabilization of actin filaments [48]. Therefore, overrep-
resentation of ACTG in steroid sensitive patients may
explain effectiveness in these patients of steroid drugs
that target ACTG.
A1BG (Alpha-1B-glycoprotein) is a plasma glycopro-
tein with homology to the immunoglobulin supergene
family [49]. Implication of this protein in responsiveness
to steroid drugs reported by Pyaphanee et al. [50] and
Huang et al. [51]. Underrepresentation of this protein in
steroid sensitive patients in our data set is thus consist-
ent with previous findings.
Conclusion
In conclusion, we discovered a panel of noninvasive urine
biomarkers using proteomics tools that are potentially
predictive of an efficient therapeutic strategy. Altogether,
21 protein candidates were identified with the most drastic
fold change exhibited by APOA-1 and MXRA8. GO-term
enrichment analysis confirmed that acute inflammatory
response is the main biological process responsible for
such differentiation. Further experiments are needed to
validate these findings and create a reliable predictive
model for steroid therapy responsiveness.
Additional files
Additional file 1: All quantified proteins using label-free quantification
method in the urine of steroid sensitive and steroid resistant patients.
Additional file 2: List of quantified proteins after preprocessing
procedure.
Additional file 3: Predictive biomarker candidates for
responsiveness to steroid therapy in FSGS patients.
Additional file 4: Gene ontology enrichment analysis of predictive
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